Email Alert RSS
Volume 15 Issue 5
Sep.  2024
Turn off MathJax
Article Contents
Abstract
References
Related Articles
DONG Kaixuan, CHEN Danni, ZHENG Ya, WANG Yuping, GUO Qinghong. The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1117-1123. DOI: 10.12290/xhyxzz.2024-0035
Citation: DONG Kaixuan, CHEN Danni, ZHENG Ya, WANG Yuping, GUO Qinghong. The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1117-1123. DOI: 10.12290/xhyxzz.2024-0035
shu

The Role of CEACAM1 in Metabolic Dysfunction-associated Steatotic Liver Disease

  • 1.

    The First School of Clinical Medicine, Lanzhou University, Lanzhou 730000, China

  • 2.

    Department of Gastroenterology, the First Hospital of Lanzhou University, Lanzhou 730000, China

  • 3.

    Gansu Province Clinical Research Center for Digestive Diseases, the First Hospital of Lanzhou University, Lanzhou 730000, China

  • 4.

    Gastrointestinal Endoscopy Center, the First Hospital of Lanzhou University, Lanzhou 730000, China

More Information
  • Corresponding author:

    GUO Qinghong, E-mail: gqh@lzu.edu.cn

  • Received Date: January 17, 2024
  • Accepted Date: February 03, 2024
  • Available Online: March 06, 2024
  • Publish Date: March 05, 2024
  • Issue Publish Date: September 29, 2024
    Graphical Abstract
    • Abstract

  • Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a transmembrane protein of the immunoglobulin superfamily, is involved in mediating cell adhesion, tissue metastasis, control of immune response, and metabolic homeostasis. Studies have shown that CEACAM1 protects the liver by promoting insulin clearance and preventing fat deposition. The down-regulation of the CEACAM1 expression level leads to a vicious cycle of insulin resistance and aggravates metabolic disorders. As CEACAM1 is critical in controlling metabolic dysfunction-associated steatotic liver disease (MASLD), stimulating its pathway or regulating its expression level might be a potential new therapeutic approach for MASLD. In this paper, therefore, we summarize the research progress of CEACAM1 in MASLD.

    • FullText(HTML)
    • References (60)
  • [1]
    Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023, 77(4): 1335-1347. DOI: 10.1097/HEP.0000000000000004
    [2]
    Loomba R, Wong V W S. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease[J]. Aliment Pharmacol Ther, 2024, 59(2): 150-156. DOI: 10.1111/apt.17846
    [3]
    Harrison S A, Dubourg J, Knott M, et al. Hyperinsuline-mia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease[J/OL]. Hepatology, 2023. doi: 10.1097/hep.0000000000000710.
    [4]
    Yanai H, Adachi H, Hakoshima M, et al. Metabolic- dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments[J]. Int J Mol Sci, 2023, 24(20): 15473. DOI: 10.3390/ijms242015473
    [5]
    Kube-Golovin I, Lyndin M, Wiesehöfer M, et al. CEACAM expression in an in-vitro prostatitis model[J]. Front Immunol, 2023, 14: 1236343. DOI: 10.3389/fimmu.2023.1236343
    [6]
    Thomas J, Klebanov A, John S, et al. CEACAMS 1, 5, and 6 in disease and cancer: interactions with pathogens[J]. Genes Cancer, 2023, 14: 12-29. DOI: 10.18632/genesandcancer.230
    [7]
    Lee W. The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes[J]. Diagn Pathol, 2011, 6(1): 40. DOI: 10.1186/1746-1596-6-40
    [8]
    Heinrich G, Ghadieh H E, Ghanem S S, et al. Loss of hepatic CEACAM1: a unifying mechanism linking insulin resistance to obesity and non-alcoholic fatty liver disease[J]. Front Endocrinol (Lausanne), 2017, 8: 8.
    [9]
    Lee W H, Najjar S M, Kahn C R, et al. Hepatic insulin receptor: new views on the mechanisms of liver disease[J]. Metabolism, 2023, 145: 155607. DOI: 10.1016/j.metabol.2023.155607
    [10]
    Russo L, Muturi H T, Ghadieh H E, et al. Liver-specific rescuing of CEACAM1 reverses endothelial and cardi-ovascular abnormalities in male mice with null deletion of Ceacam1 gene[J]. Mol Metab, 2018, 9: 98-113. DOI: 10.1016/j.molmet.2018.01.009
    [11]
    Hajihassan Z, Mohammadpour Saray M, Yaseri A. Engineering a CEACAM1 variant with the increased binding affinity to TIM-3 receptor[J]. Iran Biomed J, 2023, 27(4): 191-198.
    [12]
    Dery K J, Kojima H, Kageyama S, et al. Alternative splicing of CEACAM1 by hypoxia-inducible factor-1α enhances tolerance to hepatic ischemia in mice and humans[J]. Sci Transl Med, 2023, 15(707): eadf2059. DOI: 10.1126/scitranslmed.adf2059
    [13]
    刘传, 李丽娟, 王嵘, 等. CEACAM5在肺腺癌中的表达及临床意义[J]. 临床肺科杂志, 2022, 27(2): 256-261. DOI: 10.3969/j.issn.1009-6663.2022.02.020

    Liu C, Li L J, Wang R, et al. Expression and clinical significance of CEACAM5 in lung adenocarcinoma[J]. J Clin Pulm Med, 2022, 27(2): 256-261. DOI: 10.3969/j.issn.1009-6663.2022.02.020
    [14]
    马凯, 王鸽, 孙建兵, 等. HopQ与人CEACAM1相互作用的研究进展[J]. 医学综述, 2019, 25(17): 3433-3437. DOI: 10.3969/j.issn.1006-2084.2019.17.020

    Ma K, Wang G, Sun J B, et al. Research progress of HopQ interaction with human CEACAM1[J]. Med Recapitulate, 2019, 25(17): 3433-3437. DOI: 10.3969/j.issn.1006-2084.2019.17.020
    [15]
    Fan Y J, Yan Z P, Li T T, et al. Primordial drivers of diabetes heart disease: comprehensive insights into insulin resistance[J]. Diabetes Metab J, 2024, 48(1): 19-36. DOI: 10.4093/dmj.2023.0110
    [16]
    Schwärzler J, Grabherr F, Grander C, et al. The pathophysiology of MASLD: an immunometabolic perspective[J]. Expert Rev Clin Immunol, 2024, 20(4): 375-386. DOI: 10.1080/1744666X.2023.2294046
    [17]
    Vesković M, Šutulović N, Hrnčić D, et al. The interconnection between hepatic insulin resistance and metabolic dysfunction-associated steatotic liver disease-the transition from an adipocentric to liver-centric approach[J]. Curr Issues Mol Biol, 2023, 45(11): 9084-9102. DOI: 10.3390/cimb45110570
    [18]
    Margolis R N, Taylor S I, Seminara D, et al. Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain[J]. Proc Natl Acad Sci U S A, 1988, 85(19): 7256-7259. DOI: 10.1073/pnas.85.19.7256
    [19]
    Najjar S M. Regulation of insulin action by CEACAM1[J]. Trends Endocrinol Metab, 2002, 13(6): 240-245. DOI: 10.1016/S1043-2760(02)00608-2
    [20]
    Choice C V, Howard M J, Poy M N, et al. Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors[J]. J Biol Chem, 1998, 273(35): 22194-22200. DOI: 10.1074/jbc.273.35.22194
    [21]
    Bergman R N, Kabir M, Ader M. The physiology of insulin clearance[J]. Int J Mol Sci, 2022, 23(3): 1826. DOI: 10.3390/ijms23031826
    [22]
    Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 59(6): 2178-2187. DOI: 10.1002/hep.26988
    [23]
    De Vries M, El-Morabit F, Van Erpecum K J, et al. Non-alcoholic fatty liver disease: identical etiologic factors in patients with type 1 and type 2 diabetes[J]. Eur J Intern Med, 2022, 100: 77-82. DOI: 10.1016/j.ejim.2022.03.025
    [24]
    De Vries M, Westerink J, Kaasjager K H A H, et al. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes mellitus: a systematic review and meta-analysis[J]. J Clin Endocrinol Metab, 2020, 105(12): 3842-3853. DOI: 10.1210/clinem/dgaa575
    [25]
    Poy M N, Ruch R J, Fernstrom M A, et al. Shc and CEACAM1 interact to regulate the mitogenic action of insulin[J]. J Biol Chem, 2002, 277(2): 1076-1084. DOI: 10.1074/jbc.M108415200
    [26]
    Yousef A A, Behiry E G, Allah W M A, et al. IRS-1 genetic polymorphism (r.2963G > A) in type 2 diabetes mellitus patients associated with insulin resistance[J]. Appl Clin Genet, 2018, 11: 99-106. DOI: 10.2147/TACG.S171096
    [27]
    Poy M N, Yang Y, Rezaei K, et al. CEACAM1 regulates insulin clearance in liver[J]. Nat Genet, 2002, 30(3): 270-276. DOI: 10.1038/ng840
    [28]
    Nagaishi T, Pao L, Lin S H, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms[J]. Immunity, 2006, 25(5): 769-781. DOI: 10.1016/j.immuni.2006.08.026
    [29]
    Mahmoud A M, Szczurek M R, Blackburn B K, et al. Hyperinsulinemia augments endothelin-1 protein expression and impairs vasodilation of human skeletal muscle arterioles[J]. Physiol Rep, 2016, 4(16): e12895. DOI: 10.14814/phy2.12895
    [30]
    Abu Helal R, Muturi H T, Lee A D, et al. Aortic fibrosis in insulin-sensitive mice with endothelial cell-specific deletion of Ceacam1 gene[J]. Int J Mol Sci, 2022, 23(8): 4335. DOI: 10.3390/ijms23084335
    [31]
    Muturi H T, Ghadieh H E, Abdolahipour R, et al. Loss of CEACAM1 in endothelial cells causes hepatic fibrosis[J]. Metabolism, 2023, 144: 155562. DOI: 10.1016/j.metabol.2023.155562
    [32]
    Helal R A, Russo L, Ghadieh H E, et al. Regulation of hepatic fibrosis by carcinoembryonic antigen-related cell adhesion molecule 1[J]. Metabolism, 2021, 121: 154801. DOI: 10.1016/j.metabol.2021.154801
    [33]
    Yan M L, Li H, Xu S Y, et al. Targeting endothelial necroptosis disrupts profibrotic endothelial-hepatic stellate cells crosstalk to alleviate liver fibrosis in nonalcoholic steatohepatitis[J]. Int J Mol Sci, 2023, 24(14): 11313. DOI: 10.3390/ijms241411313
    [34]
    Laurenti M C, Dalla Man C, Varghese R T, et al. Insulin pulse characteristics and insulin action in non-diabetic humans[J]. J Clin Endocrinol Metab, 2021, 106(6): 1702-1709. DOI: 10.1210/clinem/dgab100
    [35]
    DeBose-Boyd R A, Ye J. SREBPs in lipid metabolism, insulin signaling, and beyond[J]. Trends Biochem Sci, 2018, 43(5): 358-368. DOI: 10.1016/j.tibs.2018.01.005
    [36]
    Matveyenko A V, Liuwantara D, Gurlo T, et al. Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling[J]. Diabetes, 2012, 61(9): 2269-2279. DOI: 10.2337/db11-1462
    [37]
    Ramakrishnan S K, Khuder S S, Al-Share Q Y, et al. PPARα (peroxisome proliferator-activated receptor α) activation reduces hepatic CEACAM1 protein expression to regulate fatty acid oxidation during fasting-refeeding transition[J]. J Biol Chem, 2016, 291(15): 8121-8129. DOI: 10.1074/jbc.M116.714014
    [38]
    Najjar S M, Caprio S, Gastaldelli A. Insulin clearance in health and disease[J]. Annu Rev Physiol, 2023, 85: 363-381. DOI: 10.1146/annurev-physiol-031622-043133
    [39]
    Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD-more than inflammation[J]. Nat Rev Endocrinol, 2022, 18(8): 461-472. DOI: 10.1038/s41574-022-00675-6
    [40]
    Ruck L, Wiegand S, Kühnen P. Relevance and consequence of chronic inflammation for obesity development[J]. Mol Cell Pediatr, 2023, 10(1): 16. DOI: 10.1186/s40348-023-00170-6
    [41]
    Hayakawa F, Soga K, Fujino J, et al. Utility of ultrasonography in a mouse model of non-alcoholic steatohepatitis induced by a choline-deficient, high-fat diet and dextran sulfate sodium[J]. Biochem Biophys Rep, 2023, 36: 101575.
    [42]
    Kakino S, Ohki T, Nakayama H, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model[J]. Horm Metab Res, 2018, 50(1): 80-87. DOI: 10.1055/s-0043-118666
    [43]
    DeAngelis A M, Heinrich G, Dai T, et al. Carcinoembry-onic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism[J]. Diabetes, 2008, 57(9): 2296-2303. DOI: 10.2337/db08-0379
    [44]
    Park S Y, Cho Y R, Kim H J, et al. Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1[J]. Am J Physiol Endocrinol Metab, 2006, 291(3): E517-E524.
    [45]
    Al-Share Q Y, DeAngelis A M, Lester S G, et al. Forced hepatic overexpression of CEACAM1 curtails Diet-Induced insulin resistance[J]. Diabetes, 2015, 64(8): 2780-2790. DOI: 10.2337/db14-1772
    [46]
    Wang Z Y, Sun T T, Yu J J, et al. FGF21: a sharp weapon in the process of exercise to improve NAFLD[J]. Front Biosci (Landmark Ed), 2023, 28(12): 351. DOI: 10.31083/j.fbl2812351
    [47]
    Bakker L E H, Van Schinkel L D, Guigas B, et al. A 5-day high-fat, high-calorie diet impairs insulin sensitivity in healthy, young South Asian men but not in Caucasian men[J]. Diabetes, 2014, 63(1): 248-258. DOI: 10.2337/db13-0696
    [48]
    Pezzino S, Sofia M, Mazzone C, et al. Exploring public interest in gut microbiome dysbiosis, NAFLD, and probiotics using Google Trends[J]. Sci Rep, 2024, 14(1): 799. DOI: 10.1038/s41598-023-50190-5
    [49]
    Park D J, Sung P S, Kim J H, et al. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1[J]. J Immunother Cancer, 2020, 8(1): e000301. DOI: 10.1136/jitc-2019-000301
    [50]
    Khairnar V, Duhan V, Patil A M, et al. CEACAM1 promotes CD8+ T cell responses and improves control of a chronic viral infection[J]. Nat Commun, 2018, 9(1): 2561. DOI: 10.1038/s41467-018-04832-2
    [51]
    Adams D H, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease[J]. Nat Rev Immunol, 2006, 6(3): 244-251. DOI: 10.1038/nri1784
    [52]
    He R H, Zhao S B, Cui M Y, et al. Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations[J]. Front Immunol, 2023, 14: 1234535. DOI: 10.3389/fimmu.2023.1234535
    [53]
    Horst A K, Wegscheid C, Schaefers C, et al. Carcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice[J]. Hepatology, 2018, 68(1): 200-214. DOI: 10.1002/hep.29812
    [54]
    Vallianou N, Christodoulatos G S, Karampela I, et al. Understanding the role of the gut microbiome and microbial metabolites in non-alcoholic fatty liver disease: current evidence and perspectives[J]. Biomolecules, 2021, 12(1): 56. DOI: 10.3390/biom12010056
    [55]
    Chen L F, Chen Z G, Baker K, et al. The short isoform of the CEACAM1 receptor in intestinal T cells regulates mucosal immunity and homeostasis via Tfh cell induction[J]. Immunity, 2012, 37(5): 930-946. DOI: 10.1016/j.immuni.2012.07.016
    [56]
    Gruzdev S K, Podoprigora I V, Gizinger O A. Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets[J]. Arch Microbiol, 2024, 206(2): 62. DOI: 10.1007/s00203-023-03752-0
    [57]
    Najjar S M, Perdomo G. Hepatic insulin clearance: mechanism and physiology[J]. Physiology (Bethesda), 2019, 34(3): 198-215.
    [58]
    Salehi M, Aulinger B, Prigeon R L, et al. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes[J]. Diabetes, 2010, 59(6): 1330-1337. DOI: 10.2337/db09-1253
    [59]
    Ghadieh H E, Muturi H T, Russo L, et al. Exenatide induces carcinoembryonic antigen-related cell adhesion molecule 1 expression to prevent hepatic steatosis[J]. Hepatol Commun, 2018, 2(1): 35-47. DOI: 10.1002/hep4.1117
    [60]
    Ghadieh H E, Muturi H T, Najjar S M. Exenatide prevents diet-induced hepatocellular injury in a CEACAM1-dependent mechanism[J]. J Diabetes Treat, 2017, 2017(4): JDBT-133.
    • Related Articles

  • Related Articles

    [1]CHEN Hongda, CHEN Wanqing. Evaluation of Cancer Burden Based on Big Data: Applications and Challenges in Cancer Prevention and Treatment[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 506-512. DOI: 10.12290/xhyxzz.2025-0083
    [2]LOU Ying, CAI Jun. Moving Forward the Defense Line and Wasting No Time: The Era of Active Prevention and Control of Hypertension in China Has Come[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(6): 1238-1241. DOI: 10.12290/xhyxzz.2024-0774
    [3]PAN Yuhui, SANG Wentao, BIAN Yuan, XU Feng. Sudden Cardiac Death in Hypertrophic Cardiomyopathy: Hig-risk Factors and Prevention[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 465-471. DOI: 10.12290/xhyxzz.2022-0627
    [4]LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
    [5]XU Fen, ZHOU Zhou. Heart Failure: Prevention and Treatment are Indispensable[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 953-957. DOI: 10.12290/xhyxzz.2022-0440
    [6]Chao WANG, Yang-yu ZHAO. Standardize Clinical Medication and Improve Maternal and Neonatal Outcomes: Interpretation on Prevention of Group B Streptococcal Early-onset Disease in Newborns: ACOG Committee Opinion, Number 797[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 402-407. DOI: 10.3969/j.issn.1674-9081.2020.04.008
    [7]Di ZHONG, Bo WU. Will the Strategies of Stroke Prevention Change with the New Diagnostic Standard of Hypertension?[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 103-107. DOI: 10.3969/j.issn.1674-9081.2019.02.003
    [8]Ying-xian SUN. Suggestion on China Mode of Prevention, Diagnosis and Treatment of Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(2): 97-99. DOI: 10.3969/j.issn.1674-9081.2019.02.001
    [9]Fenglin Liu, Jing Qin. From Guidelines to Practice: Analysis of Guidelines for Prevention and Management of Perioperative Venous Thrombosis in General Surgery in China[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(2): 144-149. DOI: 10.3969/j.issn.1674-9081.2018.02.008
    [10]Ying ZHANG, Jin-song GAO, Jun-tao LIU, Hai-yuan LIU, Ying-na SONG, Xiao-ming GONG, Zhi-jing SUN. Effectiveness of B-lynch Suture in Treatment and Prevention of Postpartum Hemorrhage[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(2): 174-177. DOI: 10.3969/j.issn.1674-9081.2013.02.019

  • Cited by

    Periodical cited type(4)

    1. 窦紫岩，钱文红，孔邻润，陈晔，李明亮，张静波. 非酒精性脂肪性肝病检出率现状及其影响因素：基于北京市32万人群数据. 中国全科医学. 2024(02): 144-149+155 .
    2. 王伟，缪海江，王新宇. 木香流气饮联合多烯磷脂酰胆碱胶囊对非酒精性脂肪肝肝郁脾虚证患者的效果观察. 深圳中西医结合杂志. 2024(06): 46-49 .
    3. 韩炜，宋叶君，张改萍，田晓英，付素芳，赵芳，王俊，周冉，张思宇，杜金星. 非酒精性脂肪肝病人健康减重的证据总结. 全科护理. 2024(23): 4450-4453 .
    4. 吴风，孔丽蕊，谭志群. 2型糖尿病合并NAFLD患者铁蛋白、TyG-BMI变化及与脂肪变性程度的相关性. 新疆医科大学学报. 2023(10): 1338-1343 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (522) PDF downloads (35) Cited by(6)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close